Remix Therapeutics will go public via reverse merger with Passage Bio, taking its Nasdaq listing alongside a $100M placement as it advances mRNA degrader REM-422 in cancer.
Peter Smith, Remix Therapeutics CEO
June 24, 2026 04:05 PM EDT
FinancingStartupsDeals
Remix to take Nasdaq spot of Passage Bio in reverse merger for mRNA degrader
Kyle LaHucik
Remix to go public in reverse merger with once high-flying Passage Bio
Recce Pharmaceuticals seeks $10m capital injection
Sanofi swaps R&D leaders; Merck’s Prometheus deal pays dividends
Small-Cap ProQR Therapeutics Secures Funding From Eli Lilly On Early Trial Success - ProQR Therapeutics (
FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules
Regenxbio Gains Fresh Chance As FDA Reconsiders Gene Therapy - Regenxbio (NASDAQ:RGNX)
EchoIQ set to launch $100m raise on back of Pro Medicus deal
Gene-editing startup launches with $230 million and a Chinese licensing deal
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim…
Shares bounded off their 50-day line Monday after inking a deal with Roche for a BTK-degrading drug.
Roche is set to pay Nurix Therapeutics $700 million upfront to collaborate on a BTK degrader for B-cell malignancies.
Degron Therapeutics has collected an additional $40 million for its molecular glue degrader platform; CREATE Medicines raises…
Paragon Therapeutics is taking eighth spinout Mentari Therapeutics public via a reverse merger with InMed Pharmaceuticals, paired…
Sole lead manager Ord Minnett was offering new shares at 40¢ a pop on Wednesday, representing a 13 per cent discount to the last…
